What did Iperion Limited announce?
Iperion Limited (NZX: IPR) filed “2026 Annual Report” with NZX on 30 June 2026, as an annual report announcement.
From the announcement:“Financial Results The Company reported a net loss attributable to shareholders of $294,595 for the year. This compares with a net loss attributable to shareholders of $455,683 for the previous year.”
- Which company?
- Iperion Limited (NZX: IPR)
- When was it filed?
- 30 June 2026
- Where is the original?
- NZX announcement
2026 Annual Report
IPERION LIMITED
FOR THE YEAR ENDED 31 MARCH 2026
ANNUAL REPORT
Page 1 Iperion Limited Annual Report 31 March 2026
CONTENTS
DIRECTORS’ REPORT ________________________________________________________________ 2
DIRECTORS' RESPONSIBILITY STATEMENT ________________________________________________ 4
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME _______________________ 5
STATEMENT OF FINANCIAL POSITION ___________________________________________________ 6
STATEMENT OF CHANGES IN EQUITY ____________________________________________________ 7
STATEMENT OF CASH FLOWS __________________________________________________________ 8
NOTES TO THE FINANCIAL STATEMENTS _________________________________________________ 9
INDEPENDENT AUDITOR’S REPORT ____________________________________________________ 24
CORPORATE GOVERNANCE STATEMENT ________________________________________________ 27
ADDITIONAL INFORMATION _________________________________________________________ 31
BUSINESS DIRECTORY ______________________________________________________________ 35
IPERION Limited
Page 2 Iperion Limited Annual Report 31 March 2026
DIRECTORS’ REPORT
Dear Shareholders
The Directors of Iperion Limited (“the Company” or “Iperion”) are pleased to report its financial results for the
year ended 31 March 2026.
Financial Results
The Company reported a net loss attributable to shareholders of $294,595 for the year. This compares with a net
loss attributable to shareholders of $455,683 for the previous year.
There was no sales income for the year. The improvement in result compared to the previous year is mainly a
result of discount received on the fixed outsourced manufacturing plant fee.
There were no manufacturing plant expenses for the year. The $400,000 annual fee for the fixed facility and
operating fees was fully discounted for the 2026 year in recognition of lower than expected production activity
and the plant being partially supported by research grants secured by the Operator on the ongoing development
in applications for the Pathoglaze® product.
Three Summit Ventures has also agreed to fully discount the agreed $400,000 annual fixed fee for the next two
financial years to March 2028.
Administrative expenses for the year were $294,605 decreasing by $23,176 on the prior year. Expenses remained
mostly in line with the previous year, except for higher stock exchange costs and lower costs on travel in the year.
License agreement
Iperion has the exclusive world wide licence for Pathoglaze. In recognition of the collaborative efforts
undertaken between the inventor of Pathoglaze and Iperion, agreement was reached to permanently waive the
customer and revenue performance targets under the license.
Operations and Product Development
Work undertaken has mainly focused on completing the development of Pathoglaze infused polymer jute bags
used for shipping cocoa and coffee beans. This work is being undertaken in collaboration with a multinational
chocolate manufacturer.
The Company continues to work toward securing long term sales agreements.
The Company has entered into a loan agreement Elitesoft Asia, a company related to Mr Chang Ku EE, the
majority shareholder and a director of the Company, pursuant to which Elitesoft provides a loan facility of
$250,000 to the Company at 8% interest (Hong Kong Monetary Authority Base Rate + 4%), which can be
IPERION Limited
Page 3 Iperion Limited Annual Report 31 March 2026
Directors Report - Continued
increased to US$1,000,000 subject to approval by Iperion’s shareholders. This loan replaces the NZ$150,000 loan
facility from Mr EE announced on 15 June 2026. In addition, Mr EE has also confirmed that he will provide
financial support to the Company, if required to meet its working capital obligations and liabilities as they fall due,
for at least a period of 12 months from the date of approval of the Company’s financial statements.
To provide further support to cash flow capacity, directors agreed to defer 50% of directors’ fees and 33% of the
management fee commencing from January 2026, until sufficient sales are achieved to move the company to a
positive cash flow position.
Based on an approved base case forecast with no sales and utilizing the loan facility, the Company has sufficient
cash reserves to cover its costs over the next 12 months.
On behalf of the Directors of Iperion the Company extends its thanks to the shareholders for their support of the
Company.
IPERION Limited
Page 4 Iperion Limited Annual Report 31 March 2026
DIRECTORS' RESPONSIBILITY STATEMENT
The Directors of Iperion Limited are pleased to present to shareholders the financial statements for
Iperion Limited for the year ended 31 March 2026.
The Directors are responsible for presenting financial statements in accordance with New Zealand law
and generally accepted accounting practice, which give a true and fair view of the financial position of
the Company as at 31 March 2026 and the results of its operations and cash flows for the year ended
on that date.
The Directors consider the financial statements of the Company have been prepared using accounting
policies which have been consistently applied and supported by reasonable judgements and estimates
and that all relevant financial reporting and accounting standards have been followed.
The Directors believe that proper accounting records have been kept which enable with reasonable
accuracy, the determination of the financial position of the Company and facilitate compliance of the
financial statements with the Financial Reporting Act 2013.
The Directors consider that they have taken adequate steps to safeguard the assets of the Company,
and to prevent and detect fraud and other irregularities. Internal control procedures are also
considered to be sufficient to provide a reasonable assurance as to the integrity and reliability of the
financial statements.
The Financial Statements are signed on behalf of the Board by:
Director: Bruce Dunlop Director: John Cilliers
30 June 2026
IPERION Limited
Page 5 Iperion Limited Annual Report 31 March 2026
STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE
INCOME
The accompanying notes form part of these financial statements
For the year ended 31 March 2026
YearYear
20262025
Notes$$
Interest Income - financial asset at amortised cost10 20,382
Outsourced manufacturing plant expenses2- (150,000)
Administrative expenses3(294,605) (317,781)
Depreciation, amortisation and impairment9- (8,284)
(294,595) (455,683)
Finance costs- -
Loss before income tax(294,595) (455,683)
Income tax benefit4- -
Net loss for the period attributable to shareholders(294,595) (455,683)
Other comprehensive income- -
(294,595) (455,683)
Earnings per share:centscents
Basic and diluted loss per share6(0.0572) (0.0885)
Loss before interest and tax
Total comprehensive loss for the period attributable to shareholders
IPERION Limited
Page 6 Iperion Limited Annual Report 31 March 2026
STATEMENT OF FINANCIAL POSITION
For and on behalf of the Board of Directors, dated 30 June 2026
Director: Bruce Dunlop Director: John Cilliers
The accompanying notes form part of these financial statements
As at 31 March 2026
Year
Year
2026
2025
Notes
$
$
Assets
Current assets
Cash and cash equivalents
7
155,492
425,341
GST receivable
1,196
1,384
Income tax receivable (RWT)
7,563
7,563
164,251
434,288
Non-current assets
NZX Deposit
8
20,000
20,000
20,000
20,000
Total assets
184,251
454,288
Equity and liabilities
Current liabilities
Trade and other payables
10
130,448
105,890
Total liabilities
130,448
105,890
Equity
Issued capital
5
5,672,856
5,672,856
Accumulated loss
(5,619,053)
(5,324,458)
Total equity
53,803
348,398
Total equity and liabilities
184,251
454,288
IPERION Limited
Page 7 Iperion Limited Annual Report 31 March 2026
STATEMENT OF CHANGES IN EQUITY
The accompanying notes form part of these financial statements
For the year ended 31 March 2026
Issued
capital
Accumulated
LossTotal equity
Notes$$$
As at 1 April 20255,672,856 (5,324,458) 348,398
Loss for the year- (294,595) (294,595)
Total comprehensive income- (294,595) (294,595)
At 31 March 202655,672,856 (5,619,053) 53,803
As at 1 April 20245,672,856 (4,868,775) 804,081
Loss for the year- (455,683) (455,683)
Total comprehensive income- (455,683) (455,683)
At 31 March 202555,672,856 (5,324,458) 348,398
IPERION Limited
Page 8 Iperion Limited Annual Report 31 March 2026
STATEMENT OF CASH FLOWS
The accompanying notes form part of these financial statements
For the year ended 31 March 2026
YearYear
20262025
$$
Operating activities
10 20,382
Payments to suppliers(270,047) (454,996)
Net GST refunds (paid)/received188 (2,709)
Income tax paid- (7,563)
Income tax refund received- 12,030
Net cash outflows from operating activities(269,849) (432,856)
Investing activities
Purchase of intangible assets- (8,284)
- 697,834
Net cash inflows from investing activities- 689,550
Net (decrease)/increase in cash and cash equivalents(269,849) 256,694
Cash and cash equivalents at beginning of year425,341 168,647
Cash and cash equivalents at end of year155,492 425,341
Interest received
Cash received from maturity of term deposit
IPERION Limited
Page 9 Iperion Limited Annual Report 31 March 2026
NOTES TO THE FINANCIAL STATEMENTS
For the year ended 31 March 2026
1. STATEMENT OF ACCOUNTING POLICIES
Reporting entity and statement of compliance
These financial statements and notes represent those of Iperion Limited (the “Company” or “Iperion”).
Iperion Limited is a limited liability company incorporated and domiciled in New Zealand. It is registered under
the Companies Act 1993. Iperion is listed on the NZX Main Board (“NZSX”). Iperion is a FMC reporting entity
under Part 7 of the Financial Markets Conduct Act 2013 and its financial statements have been prepared in
accordance with the Companies Act 1993, The Financial Reporting Act 2013 and the Financial Markets Conduct
Act 2013 and the NZX Main Board Listing Rules.
As at 31 March 2026 the Company is undertaking marketing and commercialisation of its product, Pathoglaze, an
antimicrobial compound.
The registered office and principal place of business are disclosed in the directory to the annual report.
Basis of preparation
The financial statements have been prepared in accordance with Generally Accepted Accounting Practice in New
Zealand (NZ GAAP). The company is a for-profit entity for the purposes of complying with NZ GAAP. The financial
statements comply with New Zealand equivalents to International Financial Reporting Standards (NZ IFRS) and
IFRS® Accounting Standards.
The information is presented in New Zealand dollars which is the Company’s functional currency and
presentation currency and is rounded to the nearest dollar.
Measurement base
The accounting principles adopted are those recognised as appropriate for the measurement and reporting of
financial performance and financial position on the historical cost basis.
Use of estimates and judgements
The preparation of financial statements in conformity with NZ IFRS requires management to make judgements,
estimates and assumptions that affect the application of accounting policies and the reported amounts of assets,
liabilities, income and expenses.
The estimates and associated assumptions are based on historical experience and various other factors that are
believed to be reasonable under the circumstances. Actual results may differ from these estimates. The estimates
and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised
in the year in which the estimates are revised and in any future periods affected.
Page 10 Iperion Limited Annual Report 31 March 2026
Deferred Tax Asset
A deferred tax asset of $663,347 (2025: $583,179) has not been recognized in the Statement of Financial Position
(note 4). The operations of the antimicrobial manufacturing operations are still in the startup stage and
production and sales activities have not commenced. As such uncertainty remains that taxable profit will be
available against which the deductible temporary differences and carry-forward of unused tax losses can be
utilised. Deferred tax asset will only be recognised when the Company commences business activities that
provide a taxable profit.
Impairment of Trademarks
The Company has registered a trademark in New Zealand and registration in other countries continues. The
trademark registration period ends in 2033 and can be renewed at the end of each registration period. The
trademark is an indefinite life intangible. The Company is yet to commence sales of the products related to the
trademark and as such future cash flows cannot be forecasted reliably. Neither can the recoverable value of the
intangible asset given the unique nature of the product and its novelty to the market. As such management have
determined that the recoverable value of the trademark at 31 March 2026 is $Nil and that it be fully impaired
(note 9).
Other than Going Concern (note 16), there were no other significant judgements and estimates in 2025 or 2026.
Material accounting policies
The following material accounting policies, which materially affect the measurement of financial performance
and financial position, have been applied.
a) Goods and services tax
All amounts are shown exclusive of Goods and Services Tax (GST), except for receivables and payables that are
stated inclusive of GST.
b) Adoption of new and revised standards
Changes in accounting policies
There are no NZ IFRS, NZ IFRIC interpretations or other applicable IFRS® Accounting Standards that are effective
for the first time for the financial year beginning on or after 1 April 2025 that had a material impact on the
financial statements.
New NZ IFRS Standards and Interpretations Issued but not yet adopted.
There are no new standards, amendments or interpretations that have been adopted or are not yet effective that
have a material impact on the company except for the below standard:
Page 11 Iperion Limited Annual Report 31 March 2026
The following amendments are effective for the period beginning 1 January 2026:
• Amendments to the Classification and Measurement of Financial Instruments – Amendments to NZ IFRS
9 Financial Instruments and NZ IFRS 7.
• Contracts Referencing Nature-dependent Electricity (Amendments to IFRS 9 and IFRS 7)
• Annual Improvements to IFRS Accounting Standards – Volume 11
The following amendments are effective for the period beginning 1 January 2027:
• NZ IFRS 18 Presentation and Disclosure in Financial Statements.
The company is currently assessing the effect of these new accounting standards and amendments.
NZ IFRS 18 Presentation and Disclosure in Financial Statements supersedes NZ IAS 1 and will result in major
consequential amendments to IFRS accounting Standards including NZ IAS 8 Basis of Preparation of Financial
Statements. Even though NZ IFRS 18 will not have any effect on the recognition and measurement of items in the
financial statements, it is expected to have a significant effect on the presentation and disclosure of certain items.
These changes include categorisation and sub-totals in the statement of profit or loss, aggregation/dis
aggregation and labelling of information and disclosure of management defined performance measures.
The accounting policies used in these financial statements have been applied consistently with those of the prior
year.
The company does not expect any other standards issued by the New Zealand Accounting Standards Board
(NZASB) or IASB, but not yet effective, to have a material impact on the company.
2. OUTSOURCED MANUFACTURING PLANT EXPENSES
The outsourced manufacturing plant expense consists of a fixed annual fee of $400,000 paid quarterly in advance
covering the rent and fixed costs of the fully equipped facility. The Company received a discount of $250,000 on
the fee for the 2025 year, and a full discount of $400,000 for the 2026 year, in recognition of lower than expected
production activity and the plant being partially supported by research grants secured by the operator for the
ongoing development in applications of the product. The annual fixed fee is fully discounted until March 2028
(note 17).
2026
2025
$
$
Outsourced manufacturing plant expenses
-
150,000
Page 12 Iperion Limited Annual Report 31 March 2026
3. ADMINISTRATION EXPENSES BY NATURE
The operating expenses generally relate to the cost associated with being a listed entity. Travel and
accommodation expenses for the current year were mainly in relation to sales and marketing activities.
*There were no other services provided to the Company by BDO Auckland.
4. TAXATION
2026
2025
$
$
Fees paid to BDO Auckland* - statutory audit
46,250
46,250
Fees paid to BDO Auckland* - statutory audit prior year
2,838
19,190
Contractors
13
42,737
44,302
Directors' fees
13
156,000
156,000
Travel and accommodation
6,396
25,335
Legal Fees
4,507
1,730
NZX Listing and registry costs
32,805
24,411
Other
3,072
563
294,605
317,781
2026
2025
$
$
Income tax benefit
Current tax
Current tax on loss for the year
(82,487)
(127,591)
Total current tax benefit
(82,487)
(127,591)
Deferred income tax
Increase in deferred tax assets [not yet recognised]
82,487
127,591
Total deferred tax benefit
82,487
127,591
Income tax benefit
-
-
Page 13 Iperion Limited Annual Report 31 March 2026
4. TAXATION - Continued
Numerical reconciliation of income tax expense to prima facie tax payable
Deferred tax asset
Company Losses to carry forward as at 31 March 2026 are $2,639,093 (2025: $2,082,781).
The deferred tax asset of $663,347 (2025: $583,179), resulting from carry forward tax losses, will only be
recognised when the Company commences business activities that provide a taxable profit (note 1).
Accounting policy: Taxation
The income tax expense or benefit for the period is the tax payable on the current period’s taxable income
adjusted by changes in deferred tax assets and liabilities attributed to temporary differences between the tax
base of assets and liabilities and their carrying amounts in the financial statements.
Current tax assets and liabilities are measured at the amount expected to be recovered from or paid to the
taxation authorities based on the current period’s taxable income. The tax rates and laws used to compute the
amount are those that are enacted or substantively enacted at reporting date.
Deferred tax assets and liabilities are recognised where the carrying amount of an asset or liability in the
statement of financial position differs from its tax base, except for differences arising on:
- The initial recognition of an asset or liability in a transaction which is not a business combination and at the
time of the transaction affects neither accounting or taxable profit, and
- Recognition of deferred tax assets is restricted to those instances where it is probable that taxable profit will be
available against which the difference can be utilised.
The income tax expense or revenue attributable to amounts recognised directly in equity are also recognised
directly in equity.
2026
2025
$
$
Loss before tax
(294,595)
(455,683)
Prima facie income tax at 28%
(82,487)
(127,591)
Subtotal
(82,487)
(127,591)
Tax losses not recognised
82,487
127,591
Income tax benefit
-
-
Tax losses carried forward
2026
2025
$
$
Opening balance
2,082,781
1,636,381
This Year
294,595
455,683
Prior year adjustment
(8,283)
(9,283)
Closing balance
2,369,093
2,082,781
Page 14 Iperion Limited Annual Report 31 March 2026
5. SHARE CAPITAL
Share Capital
All ordinary shares have been fully paid and have equal voting and dividend rights. The shares have no par value.
No shares were issued or repurchased in the current or comparative years.
The Company’s capital is managed with the objectives of maintaining adequate working capital so that all
obligations can be met on time. All components of equity are regarded as “capital”. The company is not subject to
any externally imposed capital requirements.
6. EARNINGS PER SHARE AND NET TANGIBLE ASSETS
Earnings per share
At 31 March 2026 there were 514,894,500 shares on issue (2025: 514,894,500).
The Company does not currently have any dilutive interests.
Accounting policy: Earnings per share
The company presents basic and diluted earnings per share (EPS) data for its ordinary shares. Basic EPS is
calculated by dividing the profit or loss attributable to ordinary shareholders by the weighted average number of
ordinary shares outstanding during the year, adjusted for own shares held.
Diluted earnings/(loss) per share is determined by adjusting the profit or loss attributable to ordinary
shareholders and the weighted average number of ordinary shares outstanding, for the effects of all dilutive
potential ordinary shares.
Number of
Shares
Value in $
Balance at 31 March 2026
514,894,500
5,672,856
Balance at 31 March 2025
514,894,500
5,672,856
2026
2025
Loss for the year
[ $ ]
($294,595)
($455,683)
Weighted average number of shares
514,894,500
514,894,500
Basic loss per share
[ cents ]
(0.0572)
(0.0885)
Diluted average shares on issue
514,894,500
514,894,500
Diluted loss per share
[ cents ]
(0.0572)
(0.0885)
Page 15 Iperion Limited Annual Report 31 March 2026
6. EARNINGS PER SHARE AND NET TANGIBLE ASSETS - Continued
Net tangible assets
Net tangible assets per share is a non-GAAP measure that is required to be disclosed by the NZX Listing Rules.
The calculation of the net tangible assets per share and its reconciliation to the Statement of Financial Position is
presented below:
7. CASH AND TERM DEPOSITS
Cash and cash equivalents
Accounting policy: Cash and cash equivalents
For the purpose of the statement of cash flows, cash includes cash on hand, deposits at call and short term highly
liquid deposits with maturities of three months or less.
2026
2025
Total Assets
184,251
454,288
Less:
Total Li abi l i ti es
(130,448)
(105,890)
Net Tangi bl e Assets
[ $ ]
53,803
348,398
Shares i n i ssue
514,894,500
514,894,500
Net Tangi bl e Asset per share
[ cents ]
0.0104
0.0677
2026
2025
$
$
Cash and cash equivalents: Cash at bank
155,492
425,341
Page 16 Iperion Limited Annual Report 31 March 2026
8. NZX DEPOSIT
The deposit bond held at NZX is provided as security for all amounts payable to the NZX by the Company as an
Issuer and is provided in accordance with NZX Listing Rule 1.23.
Accounting policy: Other receivables
Other receivables are recognised initially at fair value and subsequently measured at amortised cost. The carrying
amount of the asset is reduced through the use of provision accounts, and the amount of the loss is recognised in
profit or loss within ‘Administration expenses’.
9. INTANGIBLE ASSETS
A total of $17,556 has been spent on establishment of the Pathoglaze trademark. Until sales are realized on the
product, the value of the trademark is considered to be fully impaired.
Accounting policy: Trademarks and Impairment
Trademarks are carried at original cost incurred at the date of acquisition. The trademarks represents the costs
incurred on the registration of the trade name Pathoglaze. The trademark has an indefinite life and is not
amortised. Instead, the trademark is tested for impairment annually or more frequently if events or changes in
circumstances indicate that it might be impaired and is carried at cost less accumulated impairment losses.
An impairment loss is recognised for the amount by which the asset’s carrying amount exceeds its recoverable
amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal and value in use.
2026
2025
$
$
Non Current:
Bond held at NZX
20,000
20,000
2026
2025
$
$
Trademarks
Opening net book value
-
-
Additions
-
8,284
Impairment loss
1
-
(8,284)
Closing net book value
-
-
Page 17 Iperion Limited Annual Report 31 March 2026
10. TRADE AND OTHER PAYABLES
Accounting policy: Trade and other payables
Trade and other payables are initially recognised at fair value net of directly attributable transaction costs and
thereafter carried at amortised cost and due to their short term nature they are not discounted. They represent
liabilities for goods and services provided to the Company by suppliers in the ordinary course of business prior to
the end of the financial year that are unpaid and arise when the Company become obliged to make future
payments in respect of the purchase of these goods and services. The amounts are unsecured, interest free and
are usually paid within normal business trading terms, except for related party payables that are payable on
demand.
11. RECONCILIATION OF OPERATING CASHFLOW AND REPORTED LOSS
2026
2025
$
$
Current:
Trade payables
4,843
2,785
Accrued expenses
68,750
46,250
Related party payables
13
56,855
56,855
130,448
105,890
20262025
$$
Net loss for the year(294,595) (455,683)
Add/(less) non cash items
Depreciation, amortisation and impairment9- 8,284
Changes in assets and liabilities
(Increase)/decrease in Net GST receivable188 (2,709)
(Increase)/decrease in current tax asset- 4,467
Increase/(decrease) in trade and other payables1024,558 12,785
Net cash ouflows from operating activities(269,849) (432,856)
Page 18 Iperion Limited Annual Report 31 March 2026
12. FINANCIAL INSTRUMENTS
The Company has entered into a number of non-derivative financial instruments all of which are classified as
financial assets and liabilities at amortised cost. The carrying values of these items approximate their fair value.
They are listed as follows:
All financial instruments are classified as current and have maturity dates of less than twelve months, other than
the NZX deposit which is repayable on delisting of Iperion from NZX main board.
The Company is subject to a number of financial risks.
Credit risk: Financial instruments that potentially subject the Company to credit risk are bank balances and short
term deposits. The maximum exposure to credit risk at reporting date is the value of the instruments as stated in
the Statement of Financial Position. The Company only places cash on deposit with Westpac Bank which has a
Standard & Poor’s credit rating of AA- rating.
Liquidity risk: Liquidity risk represents the company's ability to meet its contractual obligations as they fall due.
As at 31 March 2026, all financial liabilities have a contractual maturity of less than 3 months. Liquidity risk was
substantially eliminated by the cash and cash equivalents balance of $155,492 (2025: $425,341) in total. The
Board regularly reviews its liquidity position by examining future cash requirements.
Interest rate risk: Interest rate risk is the risk of loss to the Company arising from adverse changes in interest
rates. Cash at bank and short term deposits are subject to interest rate risk. Changes to interest rates can impact
the Company’s financial results by affecting the interest earned on these assets. There is no interest rate risk as
cash is held in an on call account to provide liquidity to support anticipated sales activities. The company does not
earn interest on cash in the on call account.
Accounting policy: Financial instruments
Financial instruments recognised in the statement of financial position include cash and cash equivalents, term
deposits, receivables and payables. The Company has no financial instruments that are not reported in the
Statement of Financial Position.
2026
2025
$
$
Financial assets at amortised cost
Cash and cash equivalents
7
155,492
425,341
NZX deposit
8
20,000
20,000
Total Financial assets
175,492
445,341
Financial liabilities at amortised cost
Trade and other payables
10
130,448
105,890
Total financial liabilities
130,448
105,890
Page 19 Iperion Limited Annual Report 31 March 2026
12. FINANCIAL INSTRUMENTS - Continued
Accounting policy: Financial instruments - continued
Financial assets and financial liabilities are recognised when the company becomes a party to the contractual
provisions of the financial instruments.
A financial asset is derecognised when the contractual rights to cash flows from the financial asset expire, or
when the financial asset and all subsequent risks and rewards are transferred. A financial liability is derecognised
when it is extinguished, discharged, cancelled or expires.
Impairment of financial assets
The Company recognises a loss allowance for expected credit losses on receivables. The amount of expected
credit losses is updated at each reporting date to reflect changes in credit risk since initial recognition of the
respective financial instrument.
Impairment provisions are recognised based on a forward looking expected credit loss model. The methodology
used to determine the amount of the provision is based on whether there has been a significant increase in credit
risk since initial recognition of the financial asset. For those where the credit risk has not increased significantly
since initial recognition of the financial asset, twelve month expected credit losses along with gross interest
income are recognised. For those for which credit risk has increased significantly, lifetime expected credit losses
along with the gross interest income are recognised. For those that are determined to be credit impaired, lifetime
expected credit losses (‘ECL’) along with interest income on a net basis are recognised.
Lifetime ECL represents the expected credit losses that will result from all possible default events over the
expected life of a financial instrument.
The Company recognises an impairment loss in profit or loss for all financial instruments with a corresponding
adjustment to their carrying amount. The carrying amount of the financial asset is reduced by the impairment
loss directly for all financial assets. Changes in the carrying amount of the allowance account are recognised in
profit or loss.
The Company writes off a financial asset when there is information indicating that there is no reasonable
expectation of recovery. For example, when the debtor has been placed under liquidation or has entered into
bankruptcy proceedings, or in the case of trade receivables, when the amounts are over one year past due,
whichever occurs sooner. Financial assets written off may still be subject to enforcement activities under the
Company’s recovery procedures, taking into account legal advice where appropriate. Any recoveries made are
recognised in profit or loss.
Page 20 Iperion Limited Annual Report 31 March 2026
13. RELATED PARTY TRANSACTIONS AND BALANCES
Remuneration
The directors are considered to be the key management personnel of the Company.
The following table provides the compensation for key management personnel and directors, all of which are
short term benefits.
* Management and professional fees is included in Contractors expenses note 3
Related party trade and other payables
* $100,000 was received during 2019 from Mr Chang Ku EE to cover the compliance costs associated with the
change in the majority shareholder from Golden Tower New Zealand Limited to Mr EE. Actual costs were less
than the payment received. The remaining balance of $56,855 is payable on demand, is unsecured and is
included in trade and other payables (note 10).
** In order to support cash flow capacity, directors agreed to defer 50% of directors fees and 30% of the
management fee commencing from January 2026, until sufficient sales are achieved to move the company to a
positive cash flow position.
The related party trade and other payables are interest free.
2026
2025
$
$
Management and professional services fees
42,737
44,302
Directors' fees
3
156,000
156,000
198,737
200,302
2026
2025
$
$
Payables for balance of funds received for shareholder transaction costs: *
Chang Ku EE (Director and majority shareholder)
56,855
56,855
Accruals for deferred director and management fees: **
Chang Ku EE (Director and majority shareholder)
6,000
-
KC NG (Director)
7,500
-
Bruce Dunlop (Director)
4,500
-
John Cilliers (Director)
4,500
-
79,355
56,855
Page 21 Iperion Limited Annual Report 31 March 2026
RELATED PARTY TRANSACTIONS AND BALANCES - Continued
Transactions: 2026
There were no transactions with related parties during the year, other than compensation paid to directors or
their nominees, as disclosed above.
Transactions: 2025
There were no transactions with related parties during the year, other than compensation paid to directors as
disclosed above.
14. SEGMENT INFORMATION
As at 31 March 2026, the company is organised into one operating segment and one geographical segment in
New Zealand. The Operating segments are reported in a manner consistent with the internal reporting provided
to the chief operating decision maker. The chief operating decision maker is the Board of Directors.
15. COMMITMENTS AND CONTINGENT LIABILITIES
The antimicrobial license agreement, including subsequent variations, contains minimum performance targets
that set minimum royalty of 2.1% to be paid on revenue of SGD $150,000 by 30 September 2026 and 2.1% on
revenue of SGD $1m annually from 30 September 2027. Subsequent to year end, the parties have agreed that
the minimum performance targets under the license agreement be permanently waived in accordance with a
License Fee Variation Agreement, dated 26 June 2026.
In accordance with the terms of the Pilot Outsourcing Agreement entered on 20 January 2023 for the
commercialization of antimicrobial coatings, the Company will pay fixed fees of NZD$400,000 per annum towards
the setup of the facility, engagement of core personnel and subsequent services, as well as commission of 30% on
gross profit. Invoices under the Pilot Outsourcing Agreement are payable in 30-day instalments. However, the
Company has the ability to terminate the Pilot Outsourcing Agreement at any time, with prior notice to the
Licensor, with no break fees. The Vendor agreed to discount $250,000 of the fees for the year ending 31 March
2025 (note 2) and the full $400,000 annual fee for the financial year ending 31 March 2027. Subsequent to year
end, the Vendor has agreed to fully discount the annual fees until 31 March 2028.
There were no other capital commitments or contingent liabilities at 31 March 2026 (2025: $Nil).
16. GOING CONCERN
The Directors have concluded that the basis of preparation of the financial statements on a going concern basis is
appropriate.
The Company has not earned revenue for the year ended 31 March 2026 from its product, Pathoglaze.
Commercialization activities continue, but due to the nature of the product, which requires it to be incorporated
into customers’ product manufacturing processes, the time required for sales conversions is long. The Company
reported a loss of $294,595 (2025: $455,683) from continuing operations for the year ended 31 March 2026. As
at 31 March 2026, the Company reported a net total equity position of $53,803 (2025: $348,398) and negative
operating cash flows of $269,849 (2025: $432,856).
Page 22 Iperion Limited Annual Report 31 March 2026
16. GOING CONCERN - Continued
The Company is party to a Pilot Outsourcing Agreement, dated 2 September 2022, as part of Iperion’s strategy for
the commercialisation of the rights granted under the license agreement to manufacture and supply a self-
cleaning, antimicrobial, surface coating product. In accordance with the terms of the agreement, the Company
will pay fixed fees of NZD$400,000 per annum towards the rent and operation of the facility as well as
commission of 30% on gross sales. Invoices under the Pilot Outsourcing Agreement are payable in 30-day
instalments. Subsequent to year end, the Vendor has agreed to fully discount the agreed $400,000 fixed annual
fees until 31 March 2028.
Under the terms of the license agreement is a commitment for Iperion to achieve revenue of SGD$150,000 by
September 2026. Subsequent to year end, the parties have agreed that the customers number and revenue
performance targets under the license agreement be permanently waived. Iperion has the ability to terminate
the Pilot Outsourcing Agreement at any time, with prior notice to the Licensor, with no break fees. .
Subsequent to year end, Mr Chang Ku EE, a director and the majority shareholder of Iperion, confirmed that he
will provide financial support to the Company, if required to meet its working capital obligations and liabilities as
they fall due, for at least a period of 12 months from the date of approval of the Company’s financial statements.
Subsequent to year end, the company entered into a loan agreement with Mr EE pursuant to which Mr EE has
agreed to lend NZ$150,000 to the Company. The loan is interest-free and unsecured. The loan is repayable on
demand; however, Mr EE may only make a demand for repayment with the prior written agreement of the
Company's board of directors (excluding Mr EE). The Company may repay the loan, or any part of it, at any time
without penalty. The loan was subsequently replaced by a loan agreement with Elitesoft Asia Sdn. Bhd., a related
company to Mr Chang Ku EE. The loan with Elitesoft provides a loan facility of $250,000, that may be increased
to US$1,000,000 subject to shareholder approvals required under applicable law and NZX Listing Rules. The
facility is unsecured and available for working capital purposes.
The directors' cash flow forecasts assume that funding under the Elitesoft facility will be available to the Company
if required. The Company has not drawn on the full facility as at the date of approval of these financial
statements. The availability of the facility is dependent on the lender continuing to honour its funding
commitment.
Based on approved base case forecasts, which assumes no sales and assumes access to the Elitesoft facility of
$250,000, the Company expects to have sufficient liquidity to meet its forecast obligations over the next 12
months. The production processes are new and the product is new to the market and therefore uncertainty
remains regarding future sales volumes, sales margins and the timing of achieving profitable operations.
The directors have also considered that known expenditure can be managed through existing cash resources, the
agreed discount to fixed fees under the Outsourcing Agreement through to 31 March 2028, and the ability to
terminate the service agreement should sales and profitability objectives not be achieved.
However, if unplanned costs are incurred, sales do not eventuate or the agreement is not terminated in sufficient
time to manage cash flow, there is a risk that the business does not have sufficient funds to meet obligations as
and when they fall due. These factors represents material uncertainties that may cast significant doubt on the
Company’s ability to continue as a going concern. If the Company is unable to continue as a going concern, the
consequence is that Iperion may be unable to realise its assets and discharge its liabilities in the normal course of
business.
Page 23 Iperion Limited Annual Report 31 March 2026
17. SIGNIFICANT EVENTS AFTER REPORTING DATE
Subsequent to year end, Three Summit Ventures agreed to permanently waive the customer number and
revenue performance targets (note 15) and to fully discount the annual fixed fee of $400,000 until March 2028.
Subsequent to year end, the company entered into a loan agreement with Mr Chang Ku EE, a director of the
Company, pursuant to which Mr EE has agreed to lend NZ$150,000 to the Company. The loan is interest-free and
unsecured. The loan is repayable on demand; however, Mr EE may only make a demand for repayment with the
prior written agreement of the Company's board of directors (excluding Mr EE). The Company may repay the
loan, or any part of it, at any time without penalty. The loan was subsequently replaced by a loan agreement
with Elitesoft Asia, a related company to Mr Chang Ku EE. The loan with Elitesoft provides a loan facility of
$250,000, that may be increased to US$1,000,000 subject to shareholder approval. The repayment terms are
unchanged from the original $150,000 loan and the loan is unsecured, but an interest rate of Hong Kong
Monetary Authority Base Rate + 4% applies.
Page 24
BDO Auckland
INDEPENDENT AUDITOR’S REPORT
TO THE SHAREHOLDERS OF IPERION LIMITED
Opinion
We have audited the financial statements of Iperion Limited (“the Company”), which comprise the
statement of financial position as at 31 March 2026, and the statement of profit or loss and other
comprehensive income, statement of changes in equity and statement of cash flows for the year
then ended, and notes to the financial statements, including material accounting policy
information.
In our opinion, the accompanying financial statements present fairly, in all material respects, the
financial position of the Company as at 31 March 2026, and its financial performance and its cash
flows for the year then ended in accordance with New Zealand equivalents to International
Financial Reporting Standards (“NZ IFRS”) and IFRS
®
Accounting Standards.
Basis for Opinion
We conducted our audit in accordance with International Standards on Auditing (New Zealand)
(“ISAs (NZ)”). Our responsibilities under those standards are further described in the Auditor’s
Responsibilities for the Audit of the Financial Statements section of our report. We are
independent of the Company in accordance with Professional and Ethical Standard 1 International
Code of Ethics for Assurance Practitioners (including International Independence Standards) (New
Zealand) issued by the New Zealand Auditing and Assurance Standards Board, and we have fulfilled
our other ethical responsibilities in accordance with these requirements. We believe that the audit
evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.
Other than in our capacity as auditor we have no relationship with, or interests in, the Company.
Material Uncertainty Related to Going Concern
We draw attention to Note 16 of the financial statements, which indicates that the Company
incurred a net loss of $294,595 during the year ended 31 March 2026 (2025: $455,683) and, as at
that date, had net assets of $53,803 (2025: $348,398), and negative operating cash flows of
$269,849 (2025: $432,856). The Company has not yet generated revenue from the
commercialisation of Pathoglaze and, while commercialisation activities continue, uncertainty
remains regarding the timing of sales conversions and the level of future sales volumes and margins
that the product will achieve.
As disclosed in Note 16, subsequent to year end the Company obtained a $250,000 loan facility from
a related party and received confirmation of ongoing financial support from its majority
shareholder to assist the Company in meeting its obligations as they fall due. In addition, the
counterparty to the Pilot Outsourcing Agreement agreed to waive the annual fixed fees under that
agreement until 31 March 2028 and certain performance targets under the licence agreement have
been permanently waived. As stated in Note 16, these events or conditions, along with other
matters as set forth in Note 16, indicate that a material uncertainty exists that may cast significant
doubt on the Company’s ability to continue as a going concern. Our opinion is not modified in
respect of this matter.
Page 25
BDO Auckland
Key Audit Matters
Key audit matters are those matters that, in our professional judgement, were of most significance
in our audit of the financial statements of the current period. These matters were addressed in the
context of our audit of the financial statements as a whole, and in forming our opinion thereon,
and we do not provide a separate opinion on these matters. We have determined that other than
the matter described in the Material Uncertainty Related to Going Concern section, there are no
key audit matters to be communicated in our report.
Other Information
The directors are responsible for the other information. The other information comprises the
Annual Report, but does not include the financial statements and our auditor’s report thereon.
Our opinion on the financial statements does not cover the other information and we do not express
any form of audit opinion or assurance conclusion thereon.
In connection with our audit of the financial statements, our responsibility is to read the other
information and, in doing so, consider whether the other information is materially inconsistent with
the financial statements or our knowledge obtained in the audit or otherwise appears to be
materially misstated. If, based on the work we have performed, we conclude that there is a
material misstatement of this other information, we are required to report that fact. We have
nothing to report in this regard.
Directors’ Responsibilities for the Financial Statements
The directors are responsible on behalf of the Company for the preparation and fair presentation of
the financial statements in accordance with NZ IFRS and IFRS
®
Accounting Standards, and for such
internal control as the directors determine is necessary to enable the preparation of financial
statements that are free from material misstatement, whether due to fraud or error.
In preparing the financial statements, the directors are responsible on behalf of the Company for
assessing the Company’s ability to continue as a going concern, disclosing, as applicable, matters
related to going concern and using the going concern basis of accounting unless the directors either
intend to liquidate the Company or to cease operations, or have no realistic alternative but to do
so.
Auditor’s Responsibilities for the Audit of the Financial Statements
Our objectives are to obtain reasonable assurance about whether the financial statements as a
whole are free from material misstatement, whether due to fraud or error, and to issue an
auditor’s report that includes our opinion. Reasonable assurance is a high level of assurance, but is
not a guarantee that an audit conducted in accordance with ISAs (NZ) will always detect a material
misstatement when it exists. Misstatements can arise from fraud or error and are considered
material if, individually or in the aggregate, they could reasonably be expected to influence the
decisions of users taken on the basis of these financial statements.
A further description of our responsibilities for the audit of the financial statements is located at
the External Reporting Board’s website at: https://www.xrb.govt.nz/assurance-standards/auditors-
responsibilities/audit-report-2/.
This description forms part of our auditor’s report.
Page 26
BDO Auckland
Who we Report to
This report is made solely to the Company’s shareholders, as a body. Our audit work has been
undertaken so that we might state those matters which we are required to state to them in an
auditor’s report and for no other purpose. To the fullest extent permitted by law, we do not accept
or assume responsibility to anyone other than the Company and the Company’s shareholders, as a
body, for our audit work, for this report or for the opinions we have formed.
The engagement partner on the audit resulting in this independent auditor’s report is Junita Sen.
BDO Auckland
Auckland
New Zealand
30 June 2026
Page 27 Iperion Limited Annual Report 31 March 2026
CORPORATE GOVERNANCE STATEMENT
The Board of Directors (“Board”) of Iperion (“IPR”) recognise the need for strong corporate governance practices
and has adopted a comprehensive corporate governance code. The code is based on the recommendations set
out in the NZX Corporate Governance Code and the requirements of the NZX Main Board Listing Rules. The
Company’s website is currently under construction; but in the interim copies of key documents referred to in this
section can be requested by emailing john.cilliers@outlook.co.nz. The information contained in this section is
current as at 24 June 2026 and has been approved by the Board. The key documents within the code were last
reviewed effective June 2026 and a summary statement of the key documents is as follows:
Code of Ethics and Financial Products Trading Policy
Iperion has adopted policies that are designed to formalise its commitment to the highest standards of ethical
conduct and to provide all Directors and representatives with clear guidance on those standards. These are
governed by the Code of Ethics and also the Financial Products Trading Policy.
The Code of Ethics details the ethical and professional behavioural standards required of the Directors and all
employees.
The Financial Products Trading Policy details the procedure whereby Iperion Directors and employees may trade
in the Company’s shares. Directors and employees may not trade in Iperion shares when they have price sensitive
information that is not publicly available. In addition, except where the Directors have the permission of the
Board, the Directors may trade in the Company’s shares only during specified trading windows.
The Company maintains an interests register in which the particulars of certain transactions and matters involving
Directors must be recorded. Details of all matters entered into the register by individual Directors are outlined in
Note 13 of the Financial Statements.
Governance Code
The Board has adopted a Governance Code that sets out the roles and responsibilities of the Board and
distinguishes between the role and responsibilities of the Board and Management. Board's role is to direct the
Company and enhance its value for Shareholders in accordance with good governance principles. The Board
recognises that the quality with which it performs its functions is an integral part of the performance of the
Company and that there is a strong link between good governance and performance.
Role and Composition of the Board
Iperion retains a Board of Directors which aims to ensure that shareholders’ interests are held paramount. The
Board is responsible for the direction and control of Iperion and is accountable to shareholders and others for the
Company’s performance and compliance with the appropriate laws and standards. A key responsibility of the
Board is to monitor the performance of management on an ongoing basis.
The Company’s Constitution requires a minimum of three Directors with a maximum of seven. At least two of the
Directors must be ordinarily resident in New Zealand. The composition of the Board must include a minimum of
two Independent Directors. The Board elects a Chairman whose primary responsibility is the efficient functioning
of the Board. The Board is currently made up of four Directors and the Board considers that two Directors are
independent in terms of the New Zealand Exchange requirements.
Page 28 Iperion Limited Annual Report 31 March 2026
Independent Directors
• Bruce Dunlop
• John Cilliers
Director
• Chang Ku EE (Chairman)
• Kuan Chong NG
Board meetings
The Board met regularly during the year. The Board is provided with accurate timely information on all aspects of
the Company’s operations. The Board is kept informed of key risks to the Company on a continuing basis. In
addition, the Board meets whenever necessary to deal with specific matters needing attention between the
scheduled meetings.
The table below shows director attendance at board meetings during the year ended 31 March 2026:
Chang Ku EE (Chairman) -
Kuan Chong NG 10
John Cilliers 10
Bruce Dunlop 10
Diversity Policy
Iperion believes that diversity and inclusion contribute to competitive advantage and sustainable business
success which is reflected in the Companies Diversity Policy. Iperion is committed to an inclusive workplace that
fosters and promotes workplace diversity at all levels. This provides the capacity to view problems and
opportunities from many different perspectives.
Board diversity table as at 31 March 2026:
4 male directors
0 female directors
0 gender diverse directors
0 male officers
0 female officers
0 gender diverse officers
The Board believes that the current makeup of the Board is appropriate at this time.
Board Committees – Audit Finance and Risk Committee
The Board has overall responsibility for the Company’s system of risk management and internal control. The
Board has established a Committee known as the Audit, Finance and Risk Committee. The primary purpose of the
Audit, Finance and Risk Committee is to assist the Board of Iperion in fulfilling its responsibilities relating to the
company’s management systems, accounting and reporting, external and internal audit, finance and risk
management activities. The Committee comprises John Cilliers (Chairman of Committee), Bruce Dunlop and KC
Ng. Meetings are held not less than twice a year having regard to the Company’s reporting and audit cycle.
Page 29 Iperion Limited Annual Report 31 March 2026
Management tools used by Iperion include the audit committee function, outsourcing of certain functions to
experts, internal controls, financial and compliance reporting procedures and processes, business continuity
planning and insurance.
Other Committees
Due to the importance of Nomination and Remuneration matters these are addressed by the Board as a whole
and consequently there is no separate Nomination or Remuneration Committee at this time.
Continuous Disclosure
Iperion’s Market Disclosure Policy sets out the Company’s arrangements to ensure material information is
identified, reported, assessed and, where required, disclosed to the market in a timely manner. Iperion is
committed to ensuring the timely disclosure of material information about the Company to ensuring that the
Company complies with the NZX Main Board Listing Rules.
Remuneration Policy
Iperion’s Remuneration Policy is included in its Remuneration, Nomination and Health & Safety Committee
Charter which sets out the principles which apply to the remuneration of the Board and employees. Details of
individual director remuneration are outlined on page 30 and in Note 13 of the Financial Statements.
Auditors
The Audit, Finance and Risk Committee is accountable for ensuring the performance and independence of the
external auditors – BDO Auckland. The Committee also recommends to the Board, which services other than the
statutory audit, may be provided by BDO Auckland as auditors.
Shareholder Relations
The Board recognises the importance of providing comprehensive and timely information to shareholders.
Information is communicated to shareholders in the Interim Report and the Annual Report. The release of the
Annual Report is followed by the Annual Shareholders Meeting, which the Board recognises as an important
forum at which the shareholders can meet and question the Board. Full participation of shareholders is
encouraged at the Annual Shareholders Meeting to ensure a high level of accountability and identification with
the Company’s strategies and goals. Shareholders are encouraged to submit questions in writing prior to the
meeting.
Environmental, Social and Governance
Iperion recognises the importance of minimising our environmental, social and governance impact. The Company
is committed to minimise its environmental impact and achieve sustainable business practices.
Summary of Exceptions
The Company’s corporate governance code is based on the recommendations set out in the NZX Corporate
Governance Code and the requirements of the NZX Main Board Listing Rules. The Board considers that Iperion’s
corporate governance code has followed these recommendations and requirements in all material respects in the
current year with the following exceptions:
Page 30 Iperion Limited Annual Report 31 March 2026
• Recommendation 3.6 (protocols setting procedure to follow if takeover offer received including the set-
up of a separate committee) - there are no written protocols at this time but the whole Board would be
immediately involved and legal advice sought.
• Recommendation 4.4 (reporting includes non-financial disclosures such as exposure to environmental
risks and how those risks are managed) – due to the Company’s limited current operations such
reporting will be considered in future years.
• Recommendation 8.5 (the board should ensure that the notices of annual or special meetings of quoted
equity security holders is posted on the issuer’s website as soon as possible and at least 20 working days
prior to the meeting) - the Company held the 2025 Annual Meeting on 26 September 2025. The notice
of the Annual Meeting was released on 29 August 2025, being less than the 20 working days
recommended.
The alternate governance practices described above have been approved by the Board.
Page 31 Iperion Limited Annual Report 31 March 2026
ADDITIONAL INFORMATION
STOCK EXCHANGE LISTING
Iperion Ltd is listed on NZSX under the code IPR for ordinary shares.
REGISTRY
Link Market Services is Iperion’s security register manager and holds all shareholder records electronically. Link
Market Services is also responsible for the maintenance of shareholder records, Iperion’s call centre, and the
preparation of distribution payments. Contact details for Link Market Services are set out in the business
directory on the last page.
ANNUAL REPORT AND ANNUAL MEETING
All shareholders are entitled to receive a copy of the Annual Report. If you do not require the Annual Report, or if
you receive more copies than you require, please notify Link Market Services at the address shown on the last
page.
The next Annual General Meeting is intended to be held in September 2026. The Notice of Meeting and Proxy
Form will be sent shortly.
PRINCIPAL ACTIVITIES AND CHANGES IN STATE OF AFFAIRS
The Company is currently in the process of commercialisation of novel antimicrobial compounds.
DIRECTORS
The following directors held office during the financial year:
Current directors:
Chang Ku EE
Kuan Chong NG
John Cilliers
Bruce Dunlop
DIRECTORS INTEREST IN IPERION LIMITED
The following table sets out each current director’s relevant interest (direct and indirect) in shares of the
company as at the date of this report.
Directors
Fully paid
ordinary
shares
%
Chang Ku EE398,528,343 77.40%
John Ci l l i ers50,000 0.01%
Page 32 Iperion Limited Annual Report 31 March 2026
REMUNERATION
The following table provides the compensation for key management personnel and directors.
During the financial year there were no employees or former employees who received remuneration and other
benefits in their capacity as employees of the Company of which was or exceeded $100,000 per annum.
The Board received no notice during the year from directors requesting to use the Company information received
in their capacity as directors which would not have been otherwise available to them.
DIRECTORS DISCLOSURE OF INTERESTS
The following general disclosures of interest were received in relation to the year ended 31 March 2026:
Chang Ku EE
John Cilliers
• ESA Holdings Limited
• Incrementum Ltd
• C&T Graphics
• Acanthus Ltd
• Arlen Management Ltd
Kuan Chong NG
• Callisto One Ltd
• Iperion TSV Services
• Myland Partners NZ Ltd
• Soloura Ltd
Bruce Dunlop
• Vineway Ltd
• Pracsol Limited
• Western City Holdings Ltd
Director fees
Professional
services fees
Other
employee
benefits
Total
$
$
$
$
Chang Ku EE
48,000
-
-
48,000
Kuan Chong NG
36,000
36,000
-
72,000
John Cilliers
36,000
6,737
-
42,737
Bruce Dunlop
36,000
-
-
36,000
156,000
42,737
-
198,737
2026
Page 33 Iperion Limited Annual Report 31 March 2026
DISTRIBUTION OF SECURITY HOLDERS (AS AT 15 JUN 2026)
20 LARGEST SHAREHOLDERS (AS AT 15 JUN 2026)
Distribution of Secutiry Holders
Size of Holding
Number
%
Number
%
1-1000
358
74.1%
196,000
0.04%
1001-5000
16
3.3%
39,200
0.01%
5001-10000
16
3.3%
139,495
0.03%
10001-50000
28
5.8%
677,592
0.13%
50001-100000
14
2.9%
1,161,632
0.23%
Greater than 100000
51
10.6%
512,680,581
99.57%
483
100.0%
514,894,500
100.00%
Number of Securities
Number of Security Holders
Ordinary shareholdersNumber%
1Chang Ku Ee398,528,343 77.4%
2Kycz Limited44,280,927 8.6%
3Trinity Portfolio Limited9,000,000 1.8%
4Jo Ro Co Limited8,405,130 1.6%
5Robert Gregory Mcauley7,464,312 1.5%
6Roger Grice7,459,505 1.5%
7Uob Kay Hian Private Limited5,247,406 1.0%
8Russell Maloney5,015,092 1.0%
9John Sydney Philpott4,938,425 1.0%
10Lei Pei4,000,000 0.8%
11Global Paradigm2,785,714 0.5%
12Murray Horton Blackwell2,576,400 0.5%
13Custodial Services Limited2,188,212 0.3%
14Richard Black1,540,754 0.2%
15Betalert Limited668,596 0.2%
16Parminder Kumar Sharma617,750 0.1%
17M F Campbell Limited600,000 0.1%
18Christopher David Castle579,432 0.1%
19Philip Stickland500,000 0.1%
20Graeme Craig Joynt500,000 0.1%
21R & K Famularo Family413,425 0.1%
507,309,423 98.42%
Fully paid
Page 34 Iperion Limited Annual Report 31 March 2026
SUBSTANTIAL SHAREHOLDERS
As at 31 March 2026, the following holders are Substantial Product Holders in Iperion within the meaning of that
expression under Section 274 of the Financial Markets Conduct Act 2013:
VOTING RIGHTS
Under the Company’s Constitution, each member present at a general meeting is entitled:
1. on a show of hands, to one vote; and
2. on a poll, to one vote for each share held or represented.
WAIVERS
There were no waivers granted or published by the NZX in relation to Iperion or relied upon by the Company in
the 12 month period to 31 March 2026.
AUDIT FEE
Auditor’s fees are disclosed in note 3 of the financial statements.
DONATIONS
No donations were made during the year.
ANNUAL REPORT CERTIFICATE
This Annual Report is dated 30 June 2026 and is signed on behalf of the Board by:
Director: Bruce Dunlop Director: John Cilliers
HolderShares held%Classification of holding
Chang Ku Ee398,528,343 77.4%Regi stered hol der and benefi ci al owner
KYCZ Li mi ted44,280,927 8.6%Regi stered hol der and benefi ci al owner
Page 35 Iperion Limited Annual Report 31 March 2026
BUSINESS DIRECTORY
Company
number:
4844319
Directors:
Chang Ku EE, Chairman
Kuan Chong NG
John Cilliers
Bruce Dunlop
Registered
office:
Level 2 Tower Building
50 Customhouse Quay
Wellington, 6011
New Zealand
Share Registrar
Link Market Services
Level 7, Zurich House
21 Queen Street
Auckland 1010
Bankers:
Westpac Bank Limited
Solicitors:
Duncan Cotterill
Wellington
Auditors:
BDO Auckland
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- GEN — General Capital Limited: General Capital Releases 2026 Annual Report2026-06-22
“ANNUAL REPORT FOR THE YEAR ENDED 31 MARCH 2026 GENERAL CAPITAL LIMITED ANNUAL REPORT FOR THE YEAR ENDED 31 MARCH 2026 CONTENTS 01 DIRECTORS’ PROFILES 02 02 GENERAL FINANCE DIRECTORS & EXECUTIVE 03 03 DIRECTORS’ REPORT 04 04 CORPORATE GOVERNANCE STATEMENT 16 05 INDEPENDEN…”
- DGL — Delegat Group Limited: DGL - FY26 Results: Delegat delivers a strong FY26 result2026-08-27
“3 YEAR ENDED 30 JUNE20262025202420232022 Case Sales (000s)3,3203,1883,6143,6763,360 OPERATING PERFORMANCE 1 Operating Revenue 9 ($m)364.1349.6375.7375.8325.4 Operating EBITDA 1, 2 ($m)134.5116.5128.5120.4112.2 Operating EBIT 3, 4 ($m)104.189.0102.796.888.8 Operating EBIT…”
- MEE — Me Today Limited: Me Today Limited Annual Report2026-09-24
“Annual Report FOR THE YEAR ENDED 30 JUNE 2026 Contents CHAIR & CEO REPORT DIRECTORS’ PROFILES FINANCIAL STATEMENTS Consolidated Statement of Profit and Loss and Other Comprehensive Income Consolidated Statement of Changes in Equity Consolidated Statement of Financial…”